Merck Serono, the new division of Merck for innovative small molecules and biopharmaceuticals, was established following the acquisition of Serono and the integration of its business with the former Merck Ethicals Division. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, produces and commercialises innovative products to help patients with diseases with unmet needs. Our North American business operates in the United States and Canada under EMD Serono.

Merck Serono has leading brands serving patients with cancer, multiple sclerosis, infertility, metabolic and cardiometabolic disorders, as well as psoriasis. With an annual research and development investment of one billion euros, we are committed to growing our business in specialist-focused therapeutic areas, such as neurodegenerative diseases and oncology, as well as new therapeutic areas potentially arising out of our research and development in autoimmune and inflammatory diseases.

Merck Serono’s Disease Modifying Drug (DMD) is used to treat relapsing forms of multiple sclerosis, and is registered in more than 80 countries worldwide.